Two new trials saw no impact of thrombolytics in reducing disability at 90 days, but some positive signals offer hope.

Two randomized trials found that intra-arterial urokinase and tenecteplase did not improve functional outcomes after ...

Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

NDAQ:HUMA) Humacyte Provides Update on Commercial Launch and Pricing of Symvess(TM) (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

Men vs women with spontaneous intracerebral hemorrhage (ICH) have a higher risk for deep bleeds but a lower risk for poor outcomes.